Literature DB >> 32134160

Osteoradionecrosis in osseous free flap reconstruction: Risk factors and treatment.

Peter T Dziegielewski1,2,3, Stewart Bernard1,3, William M Mendenhall2,4,3, Kathryn E Hitchock2,4,3, Charles Parker Gibbs5,3, Joy Wang6,3, Robert J Amdur2,4,3, Natalie L Silver1,2,3, John Hardeman7,3, Hadi Seikaly7,3, William J Reschly1,3, Deepa Danan1,3, Raja Sawhney1,3.   

Abstract

OBJECTIVE: To determine the rate and risk factors for osteoradionecrosis (ORN) in osseous free flaps after postoperative radiation therapy (PORT). To describe the treatment of free flap ORN.
METHODS: Seventy-four patients undergoing osseous free flap reconstruction were analyzed. Thirty-eight completed PORT. Patients were followed for ≥6 months.
RESULTS: The rate of ORN was 34% overall; 0% with 50 to 59.9 Gy; 8% with 60 Gy; 40% with 66 Gy; 56% with 70 to 74.4 Gy. Mean time to ORN was 13.1 months. 0/28 patients without PORT developed free flap osteonecrosis. Multivariate analysis found the only factor predicting ORN: PORT >60 Gy, which increased the risk 21-fold. Treatment included PENTACLO, hyperbaric oxygen, and surgical debridement with 75% within 2 years.
CONCLUSION: PORT >60 Gy is significantly associated with free flap ORN. As the dose of adjuvant RT increases beyond 60 Gy, the risk of ORN in free flaps rises. Consideration should be given to lower PORT doses or delaying free flap reconstruction when feasible.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  fibula free flap; free flap; head and neck cancer; osteoradionecrosis; radiation therapy

Mesh:

Year:  2020        PMID: 32134160     DOI: 10.1002/hed.26118

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

Review 1.  Current Role of Radiotherapy in the Management of Oral Cavity Squamous Cell Carcinoma.

Authors:  William M Mendenhall; Adam L Holtzman; Roi Dagan; Curtis M Bryant; Kathryn E Hitchcock; Robert J Amdur; Rui P Fernandes
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2020-11-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.